Full history for every metric is available with a Kvantra account
VectivBio Holding AG (VECT)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 27 | 27 |
| Operating profit | $m | -81 | -81 | |||||
| Net profit | $m | - | - | -24 | -60 | -87 | -94 | -94 |
| EPS reported | $ | -2.12 | -2.12 | |||||
| Operating cashflow per share | $ | -1.27 | -1.27 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.28 | -1.28 | |||||
| Free cash flow | $m | -56 | -56 | |||||
| Net debt | $m | -211 | -211 | |||||
| Book value equity | $m | 213 | 213 | |||||
| Book value per share | $ | 4.84 | 4.84 | |||||
| Number of shares | m | 44.13 | 44.13 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.79 | 4.97 | |||||
| P/S LTM | x | 13.98 | 38.75 | |||||
| P/FCF LTM | x | -6.79 | -18.81 | |||||
| EV/EBITDA LTM | x | -2.15 | -10.64 | |||||
| EV/Sales LTM | x | 6.27 | 31.03 | |||||
| Earnings Yield LTM | % | -24.51% | -12.59% | |||||
| FCF Yield | % | -14.73% | -5.32% | |||||
| Quality | ||||||||
| ROE | % | -43.93% | -56.92% | |||||
| ROIC | % | -35.32% | -35.32% | |||||
| Operating margin | % | -294.52% | -294.52% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -206.04% | -206.04% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -5.38 | -5.38 | |||||
| Net Debt/EBITDA | x | 2.64 | 2.64 | |||||
| EBIT/Net interest | x | -25.45 | -25.45 | |||||
| Net debt/market cap | % | -55.17% | -19.93% | |||||
| Net debt/Equity | x | -0.99 | -0.99 | |||||
| Gross debt/equity | x | 0.05 | 0.05 | |||||
Company overview
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
VectivBio Holding AG (VECT)
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free